Chromosome Banding Analysis in CLL Panagiotis Baliakas, MD-PhD
|
|
- Alvin Ray
- 5 years ago
- Views:
Transcription
1 Chromosome Banding Analysis in CLL Panagiotis Baliakas, MD-PhD Dept of Immunology, Genetics and Pathology Science for Life Laboratory, Uppsala University Medical Genetics, University Hospital, Uppsala
2 Cytogenetic analysis is clinically relevant in hematology Döhner H et al. Blood 2017
3 Cytogenetic analysis is clinically relevant in hematology Greenberg PL et al. Blood 2012
4 Do we think genetically in CLL?
5 Döhner H et al. N Engl J Med 2000 Puente et al. Nature 2011/Wang et al. N Engl J Med Jeronim et. Leukemia 2014/Baliakas et al. Leukemia 2015 Do we think genetically in CLL? 11q del Isolated del13q 13q del only 12q trisomy Is there still a place for chromosome banding analysis (CBA) 17p del (N = 325) Normal in CLL? Time (months)
6 CBA in CLL travelling back in time......the frequency of chromosomal abnormalities in the disease appears to be much higher than has previously been thought... Blood 1980
7 Cytogenetic complexity in CLL: clinical considerations Juliusson G et al. NEJM 1990 Dierlamm J et al. Cancer Gent Cytogen 1997
8 Survival (%) Temporarily at the backstage Is FISH-analysis enough? p del (N = 325) 11q del Time (months) 13q del only Isolated del13q Is FISH-analysis informative of the 12q trisomy actual clonal cytogenetic background? Should we care about aberrations that 20 Normal are not detected by FISH? Döhner H et al. N Engl J Med 2000
9 Missing the forest for the trees? Cases with normal FISH or isolated del(13q) may harbor complex karyotype without CK with CK Baliakas et al. AJH 2014
10 Cytogenetic complexity in CLL open issues What is the predictive significance? Which are the actual links to TP53 abnormalities? What is the significance of complex karyotype in the era of novel agents?
11 Cytogenetic complexity inferior outcome after FCR...patients without presence of chromosome 17 or complex cytogenetic abnormalities demonstrated better response duration and survival after therapy. Badoux XC et al. Blood 2011
12 Cytogenetic complexity inferior outcomes in CLL11 Herling CD et al. Blood 2016
13 Cytogenetic complexity predicts for inferior outcome to ibrutinib in R/R CLL Thompson PA. Cancer 2015
14 Cytogenetic complexity predicts for inferior outcome to ibrutinib in R/R CLL CK was associated with inferior OS (25 months) independently of del(17p) Concerns Low number of cases No data on TP53 mutations Different treatment regimens Thompson PA. Cancer 2015
15 Idelalisib may overcome the adverse impact of cytogenetic complexity in R/R CLL Kreuzer KA. ASH 2016
16 Idelalisib may overcome the adverse impact of cytogenetic complexity in R/R CLL Kreuzer KA. ASH 2016
17 Idelalisib may overcome the adverse impact of complex karyotype in R/R CLL No impact of CK or TP53abs on PFS or OS for CLL patients treated with Idelalisib-R Concerns Very low success rate regarding CBA Short follow up Kreuzer KA. ASH 2016
18 Cytogenetic complexity predicts for inferior outcome to venetoclax in R/R CLL Anderson MA et al. Blood 2017
19 Cytogenetic complexity predicts for inferior outcome to venetoclax in R/R CLL Concerns Low number of patients Heterogeneous prior treatment regimens No prior exposure to BcR inhibitors No multivariate analysis
20 Cytogenetic complexity in CLL - open issues What is the clinically relevant definition of complex karyotype in CLL? Is the number or the type of aberrations that explain the unfavorable clinical outcome? What are the actual links with TP53 abnormalities?
21 ERIC: joining forces 5479 pts from 17 European Institutions 5290 pts included 10 metaphases 96.5% success n=5290 n, % Male Female Median age diagnosis <55 >70 MBL Binet A Binet B Binet C 3302, 62% 1988, 38% 64.6 years 1157/5231, 22% 1633/5231, 31% 383/4454, 9% 3030/4454, 68% 753/4454, 17% 288/4454, 6% U-CLL 1514/3453, 44% TP53abs 657/4968, 13% del(11q) 601/4834, 12% Trisomy /4719, 17% del(13q) 2541/4750, 53% Treated (median FU: 5.9 years) 2314/4875, 48% Baliakas et al. In preparation
22 Time of the analysis 6m from diagnosis 12m from diagnosis 18m from diagnosis Before treatment/ Untreated pts 3540/5179, 68% 3784/5179, 73% 3968/5179, 77% 4447/4868, 91% Methodology CPG/IL2 TPA TPA-CPG/IL2 939, 18% 2630, 50% 1720, 32% Baliakas et al. In preparation
23 Overview of chromosomal aberrations 3abs n=355 (46%) All patients n=5479 Patients with 10 metaphases n=5290 (97%) Stimulation Protocol Comlex Karyotype (CK) n=794 (15%) CK ( 3abs) Non-CK n=4496 (85%) CK ( 5abs) CPG/IL2 253/934, 27% 92/934, 10% TPA 259/2518, 10% 80/2518, 4% 4 abs n=168 (22%) 5abs n=251 (32%) Normal/del(13q) n=2659 (59%) 1 abn (non-del(13q)) n=1122, 25% 2abs n=715, 16% Baliakas et al. In preparation
24 Overview of chromosomal aberrations Normal/del(13q) FISH in 551 CK (3 abs) cases with available FISH data: n=156, 28% Cases with CK ( 3abs) and normal/del(13q) FISH 3abs 4abs 5abs 86/289, 30% 28/124, 23% 39/189, 21% Baliakas et al. In preparation
25 Impact of CK ( 3 aberrations) on clinical outcome 100% nonck, n=4360 CK, n=735 75% % Alive 50% 25% p< % Time (years from CBA) OS is measured from date of the chromosomal analysis until death or last follow-up Baliakas et al. In preparation
26 Impact of CK ( 3 aberrations) on clinical outcome N=2376 HR 95% CI p-value Male CK < Trisomy del(11q) TP53abs < U-CLL < Binet A < Baliakas et al. In preparation
27 Is cytogenetic complexity always bad?
28 The +12,+19 story +12,+19,+other trisomy (n=43) +12,+19,+structural (n=38) P-value Age, (median) Male 33/43 30/ Binet B/C 8/39 6/ M-CLL 19/21 32/ del(13q) 39/43 30/ del(11q) 0/39 1/ TP53abs 2/41 1/ Baliakas et al. In preparation
29 The +12,+19 story 100% 75% % Alive 50% +12,+19,+other trisomy, n=40 +12,+19,+structural abnormality, n=36 25% p=0.58 0% Time (years from CBA)
30 The +12,+19 story 100% % Alive 75% 50% +12,+19,+other, n=76 nonck, n=4292 CK, n=658 25% p< % Time (years from CBA)
31 Number of aberrations 3abs 4abs 5abs U-CLL 130/240, 54% 69/111, 62% 109/143, 76% del(11q) 86/320, 27% 47/148, 31% 48/223, 21% TP53abs 89/341, 26% 62/160, 38% 157/243, 65% * * Baliakas et al. In preparation
32 3abs vs 4abs vs 5abs Baliakas et al. In preparation
33 3abs vs 4abs vs 5abs vs other Baliakas et al. In preparation
34 3abs vs 4abs vs 5abs vs other non TP53abs Baliakas et al. In preparation
35 3abs vs 4abs vs 5abs vs other within TP53abs 100% 75% TP53abs/non CK, n=320 TP53abs/3abs, n=83 TP53abs/4abs, n=57 TP53abs/>4abs, n=147 % Alive 50% 25% p< Time (years from CBA) Baliakas et al. In preparation
36 Only high-complexity is independently associated with a worse clinical outcome N=2376 HR 95% CI p-value Male abs abs Trisomy del(11q) TP53abs < U-CLL < Binet B/C <0.0001
37 Conclusions Cytogenetic complexity is an independent prognostic marker in CLL Not all complex karyotypes are equivalent Low and intermediate complexity (3 or 4 abs) impact on outcome only if accompanied by TP53abs High complexity ( 5abs) is associated homogeneously with the worst clinical outcome independently of TP53abs and IGHV SHM status There is a place for CBA in CLL
38 G. Papanicolaou Hospital, Thessaloniki, GR Niki Stavroyianni Giwrgos Papaiwannou Michalis Iskas Achilles Anagnostopoulos Anastasia Athanasiadou MLL Munich Leukemia Laboratory, Germany Sabine Jeromin Claudia Haferlach Spanish Cytogenetic Group Anna Puiggros Julio Delgado Pau Abrisqueta Rosa Collado M Jose Calasanz Neus Ruiz-Xiville Carolina Moreno Blanca Espinet Laboratoire d hématologie, Hopital Avicenne, France Fanny Baran Marszak Virginie Eclache Florence Cymbalista Hematology Department and University Pierre et Marie Curie, Hopital Pitie-Salpetriere, Paris, France Florence Nguyen Khac Fred Davi Hematology Section, University of Ferrara, Italy Rigolin Gian Matteo Antonio Cuneo CERTH, Thessaloniki, GR Evangelia Stalica Aliki Xochelli Kostas Stamatopoulos Academic Medical Center Amsterdam, Netherlands Alexander C. Leeksma Arnon Katter Division of Hematology, Department of Medicine, University of Padua Andrea Visentin Livio Trentin CEITEC, Masaryk University, Brno, Czech Republic Karla Plevova Jana Kotaskova Kristina Durechova Michael Doubek Sarka Pospisilova Department of Haematology, Royal Bournemouth Hospital, UK Zadie Davis David Oscier First Department of Propaedeutic Medicine, University of Athens, Greece Theodoros Iliakis Panayotis Panayotidis Department of Hematology, Ljubljana University,Slovenia Helena Podgornik ERIC, The European Research Initiative on CLL Paolo Ghia
39 Thank you for your attention
Chronic Lymphocytic Leukemia. Paolo Ghia
Chronic Lymphocytic Leukemia Paolo Ghia Complex Karyotype: a novel predictive marker? Thompson PA et al. Cancer 2015 Complex karyotype superseded del(17p) Anderson MA et al. Blood 2017 Ibrutinib and Idela
More informationIgCLL group activities in 2009 and beyond. Kostas Stamatopoulos Hematology Department and HCT Unit George Papanicolaou Hospital, Thessaloniki, Greece
IgCLL group activities in 2009 and beyond Kostas Stamatopoulos Hematology Department and HCT Unit George Papanicolaou Hospital, Thessaloniki, Greece Troubleshooting Standardization Standardization and
More informationPrevalence of BTK and PLCγ2 Mutations in Patients relapsing under Ibrutinib. Lydia Scarfò Silvia Bonfiglio Lesley Ann Sutton
Prevalence of BTK and PLCγ2 Mutations in Patients relapsing under Ibrutinib Lydia Scarfò Silvia Bonfiglio Lesley Ann Sutton Patients relapsing on ibrutinib are the new unmet clinical need Woyach J et al.
More informationGenomic complexity and arrays in CLL. Gian Matteo Rigolin, MD, PhD St. Anna University Hospital Ferrara, Italy
Genomic complexity and arrays in CLL Gian Matteo Rigolin, MD, PhD St. Anna University Hospital Ferrara, Italy Clinical relevance of genomic complexity (GC) in CLL GC has been identified as a critical negative
More informationSupplemental data. EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic. leukemia
Supplemental data EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia Emma Young 1*, Daniel Noerenberg 2*, Larry Mansouri 1, Viktor Ljungström 1, Mareike Frick 2,
More informationBiomarkers in Chronic Lymphocytic Leukemia: the art of synthesis. CLL Immunogenetics. Overview. Anastasia Chatzidimitriou
Biomarkers in Chronic Lymphocytic Leukemia: the art of synthesis CLL Immunogenetics Overview Anastasia Chatzidimitriou Belgrade March 17, 2018 B cells: multiple receptors B cell receptor IG unique signature
More informationL approccio terapeu-co. Maria Rosaria Villa U.O.C. Ematologia P.O. Ascalesi ASLNA1Centro
L approccio terapeu-co Maria Rosaria Villa U.O.C. Ematologia P.O. Ascalesi ASLNA1Centro DISCLOSURE Nome: Maria Rosaria Cognome: Villa Impiego nell industria farmaceu7ca negli ul7mi 5 anni: NO Interssi
More information39 th General Assembly of ERIC members. Sunday, 6 th of December 2015 (Orlando, Florida)
39 th General Assembly of ERIC members Sunday, 6 th of December 2015 (Orlando, Florida) Agenda 07:30 08:00 EXECUTIVE COMMITTEE REPORT Introduc>on, membership update and ERIC ac>vi>es during 2015 P. Ghia
More informationNGS IMMUNOGENETICS IN CLL RESEARCH. Andreas Agathangelidis Post-doc researcher Institute of Applied Biosciences, CERTH
NGS IMMUNOGENETICS IN CLL RESEARCH Andreas Agathangelidis Post-doc researcher Institute of Applied Biosciences, CERTH ERIC & Euroclonality-NGS workshop Rotterdam, 24 November 2017 1. NGS Immunoprofiling
More informationTP53 mutational profile in CLL : A retrospective study of the FILO group.
TP53 mutational profile in CLL : A retrospective study of the FILO group. Fanny Baran-Marszak Hopital Avicenne Bobigny France 2nd ERIC workshop on TP53 analysis in CLL, Stresa 2017 TP53 abnormalities :
More informationAdvances in the treatment of Chronic Lymphocytic Leukemia
Advances in the treatment of Chronic Lymphocytic Leukemia Lab of B Cell Neoplasia - Division of Experimental Oncology Strategic Research Program on CLL Department of Onco-Hematology Università Vita-Salute
More information1. What to test. 2. When to test
Biomarkers: the triad of questions 1. What to test 2. When to test 3. Who to test Biomarkers: the triad of questions 1. What to test 2. When to test 3. Who to test Impact of CLL biological features on
More informationAdvances in CLL 2016
Advances in CLL 2016 The Geoffrey P. Herzig Memorial Symposium, Louisville, KY Kanti R. Rai, MD Northwell-Hofstra School of Medicine Long Island Jewish Medical Center New Hyde Park, NY Disclosures Member
More informationTranslocations and clonality detection in lymphoproliferative disorders by capturebased Next-generation sequencing
Translocations and clonality detection in lymphoproliferative disorders by capturebased Next-generation sequencing Dörte Wren MSc MPhil on behalf of the EuroClonality-NGS consortium Molecular Diagnostics
More informationManagement of CLL in the Targeted Therapy Era
Management of CLL in the Targeted Therapy Era Jennifer A. Woyach, MD The Ohio State University The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove
More informationERIC TP53 Network activities and outcomes. Sarka Pospisilova
ERIC TP53 Network activities and outcomes Sarka Pospisilova ERIC TP53 NETWORK 11 Training Centres 3 Certifying Centres Uppsala/Stockholm Belfast Copenhagen Amsterdam Paris Ulm Novara Brno Bellinzona Salamanca
More informationEfficacy of Bendamustine and rituximab in a real-world patient population
Efficacy of Bendamustine and rituximab in a real-world patient population Median follow-up 37,1 months Efficacy of bendamustine and rituximab as first salvage treatment in CLL and indirect comparison with
More informationManagement of 17p Deleted CLL Patients in the Era of Targeted Therapy
Management of 17p Deleted CLL Patients in the Era of Targeted Therapy Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute Associate Professor Harvard Medical School November 11,
More informationCLL Brad Kahl, MD Professor of Medicine
CLL 2016 Brad Kahl, MD Professor of Medicine Disclosures Advisory Committee Consulting Agreements Contracted Research Roche Laboratories Inc, Takeda Oncology Bristol-Myers Squibb Company, Celgene Corporation,
More informationChronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD
Chronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang-Mai University Outline
More informationshort report Summary Keywords: chronic lymphocytic leukaemia, complex karyotype, gene expression profile, overall survival, time to first treatment.
short report In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics Gian Matteo
More informationPatients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ ATM FISH deletions
/, 2017, Vol. 8, (No. 33), pp: 54297-54303 Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ ATM FISH deletions Anna Puiggros 1,2, Rosa Collado
More informationLEUCEMIA LINFATICA CRONICA
LEUCEMIA LINFATICA CRONICA Gianluca Gaidano SCDU Ematologia Dipartimento di Medicina Traslazionale Università del Piemonte Orientale Novara Outline CLL biology and pathogenesis Prognostication and prediction
More informationBASIC PROCEDURES SAMPLING, MATERIAL, SANGER SEQUENCING
Technical aspects of TP53 mutation analysis: BASIC PROCEDURES SAMPLING, MATERIAL, SANGER SEQUENCING Sarka Pavlova University Hospital and Masaryk University, Brno, Czech republic TP53 gene in CLL: KEEP
More informationGeorg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria
Chronic lymphocytic Leukemia Georg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria georg.hopfinger@wgkk.at CLL Diagnosis and Staging Risk Profile Assessment
More informationFCR and BR: When to use, how to use?
FCR and BR: When to use, how to use? Mitchell R. Smith, M.D., Ph.D. Director of Lymphoid Malignancy Program Taussig Cancer Institute Cleveland Clinic, Cleveland, OH DEBATE ISSUE 2013: Which is the optimal
More informationWe Can Cure Chronic Lymphocytic Leukemia with Current / Soon to be Approved Agents: CON ARGUMENT
We Can Cure Chronic Lymphocytic Leukemia with Current / Soon to be Approved Agents: CON ARGUMENT Danielle M. Brander, MD Duke University Division of Hematologic Malignancies & Cell Therapy CLL & Indolent
More informationCLL Biology and Initial Management. Gordon D. Ginder, MD Director, Massey Cancer Center Lipman Chair in Oncology
CLL Biology and Initial Management Gordon D. Ginder, MD Director, Massey Cancer Center Lipman Chair in Oncology CLL- Epidemiology Most common adult leukemia 25-30% in western world Incidence in US 4.5
More informationChronic lymphocytic leukemia. E. Van Den Neste Cliniques UCL Saint-Luc, Brussels Post-ASH meeting January 2015
Chronic lymphocytic leukemia E. Van Den Neste Cliniques UCL Saint-Luc, Brussels Post-ASH meeting January 2015 Disclosures Travelling to ASH: Roche Consulting services: Janssen Questions in CLL: answers
More informationUpdate on the International Harmonised Approach for Residual Disease Monitoring in Chronic Lymphocytic Leukaemia: 8-CLR flow cytometry
Update on the International Harmonised Approach for Residual Disease Monitoring in Chronic Lymphocytic Leukaemia: 8-CLR flow cytometry Andy C. Rawstron on behalf of ERIC consortium Timeline for development
More informationCLL Ireland Information Day Presentation
CLL Ireland Information Day Presentation 5 May 2018 Professor Patrick Thornton Consultant Haematologist, Senior Lecturer RCSI, and Clinical Director Hermitage Medical Clinic Laboratory Chronic Lymphocytic
More informationChronic lymphocytic Leukemia
Chronic lymphocytic Leukemia after IwCLL, ICML and EHA 2017 Ann Janssens, MD, PhD Hematology, UZ Leuven Brussels, 14 september 2017 Front line treatment CLL Active or progressive disease No active or progressive
More informationTP53 Certification overview and results of round 3
TP53 Certification overview and results of round 3 Sarka Pospisilova Jitka Malcikova CEITEC, Masaryk University and University Hospital, Brno, Czech Rep. 41st ERIC General Assembly, Copenhagen, June 9th,
More informationSubmitted to Leukemia as a Letter to the Editor, May Male preponderance in chronic lymphocytic leukemia utilizing IGHV 1-69.
Submitted to Leukemia as a Letter to the Editor, May 2007 To the Editor, Leukemia :- Male preponderance in chronic lymphocytic leukemia utilizing IGHV 1-69. Gender plays an important role in the incidence,
More informationCLL what do I need to know as an Internist in Taimur Sher MD Associate Professor of Medicine Mayo Clinic
CLL what do I need to know as an Internist in 218 Taimur Sher MD Associate Professor of Medicine Mayo Clinic Case 1 7 y/o white male for yearly medical evaluation Doing well and healthy Past medical history
More informationBendamustine + Rituximab (BR) Project
Bendamustine + Rituximab (BR) Project Efficacy and tolerability of Bendamustine and Rituximab in first line and second line treatment in CLL An observational study proposed by the ERIC-GIMEMA groups Rationale
More informationThe 1 World Congress on Controversies in Hematology (COHEM) Rome, September 2010
The 1 World Congress on Controversies in Hematology (COHEM) Rome, September 2010 Is the wait and watch philosophy still practical in the treatment of CLL even in younger patients? Expected to say NO Federico
More informationBackground. Approved by FDA and EMEA for CLL and allows for treatment without chemotherapy in all lines of therapy
Updated Efficacy and Safety From the Phase 3 RESONATE-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Abstract
More informationThe role of cytogenomics in the diagnostic work-up of Chronic Lymphocytic Leukaemia
The role of cytogenomics in the diagnostic work-up of Chronic Lymphocytic Leukaemia Adrian Zordan, Meaghan Wall, Ruth MacKinnon, Pina D Achille & Lynda Campbell Victorian Cancer Cytogenetics Service (VCCS)
More informationallosct and CLL in the BCRi era time for a study
allosct and CLL in the BCRi era time for a study Patient characteristics in BCRi studies and allosct candidates DIFFER Facts on BCRi no Cure Risk factors for shorter BCRi efficacy in MV analysis? PA-refractory
More informationGenomic and transcriptomic sequencing in chronic lymphocytic leukemia
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1259 Genomic and transcriptomic sequencing in chronic lymphocytic leukemia DIEGO CORTESE ACTA UNIVERSITATIS UPSALIENSIS
More informationHighlights of ICML 2015
Highlights of ICML 2015 Jonathan W. Friedberg M.D. Director, James P. Wilmot Cancer Center Statistics, ICML 2015: a global meeting Almost 3700 participants. 90 countries represented. Attendees: USA 465
More informationShort Telomeres Predict Poor Prognosis in Chronic Lymphocytic Leukemia
Short Telomeres Predict Poor Prognosis in Chronic Lymphocytic Leukemia L. Yang Internal Medicine Resident University of Manitoba Supervisor: Dr. J. Johnston Prognostic factors Clinical course is unpredictable
More informationCLL & SLL: Current Management & Treatment. Dr. Peter Anglin
CLL & SLL: Current Management & Treatment Dr. Peter Anglin Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of blood cell B lymphocyte Lymphocytic Cancer of white blood
More informationBIOGRAPHICAL SKETCH. DEGREE (if applicable)
BIOGRAPHICAL SKETCH NAME: Stavroula Ntoufa POSITION TITLE: Post-doctoral researcher EDUCATION/TRAINING INSTITUTION AND LOCATION DEGREE (if applicable) Completion Date MM/YYYY FIELD OF STUDY Democritus
More informationPROGNOSTICATION IN CLL: PRESENT AND FUTURE
PROGNOSTICATION IN CLL: PRESENT AND FUTURE Gianluca Gaidano, M.D., Ph.D. Division of Hematology Department of Translational Medicine Amedeo Avogadro University of Eastern Piedmont Novara-Italy CLL: Homogeneous
More informationLEUCEMIA LINFATICA CRONICA: TERAPIA DEL PAZIENTE IN RECIDIVA
CORSO TEORICO-PRATICO PER LA GESTIONE OTTIMALE DEI PAZIENTI AFFETTI DA LINFOMA MANTELLARE, LINFOMA FOLLICOLARE E LEUCEMIA LINFATICA CRONICA Torino, 21-23 Maggio 2018 LEUCEMIA LINFATICA CRONICA: TERAPIA
More informationUpdate on the ERIC TP53 Network Activities and TP53 Certification Overview and Results of Round 4
Update on the ERIC TP53 Network Activities and TP53 Certification Overview and Results of Round 4 Sarka Pospisilova Jitka Malcikova CEITEC, Masaryk University and University Hospital Brno, Czech Republic
More informationLa lenalidomide: meccanismo d azione e risultati terapeutici. F. Ferrara
La lenalidomide: meccanismo d azione e risultati terapeutici F. Ferrara MDS: new treatment goals Emerging treatment options expected to facilitate shift from supportive care to active therapy in MDS New
More informationRichter s Syndrome: Risk, Predictors and Treatment
Richter s Syndrome: Risk, Predictors and Treatment 10/23/2015 John N. Allan MD Assistant Professor of Medicine Division of Hematology and Medical Oncology CLL Research Center Weill Cornell Medicine Agenda
More informationChronic Lymphocytic Leukemia: Prognostic Factors, Supportive Care Issues and Therapeutic Advances
Chronic Lymphocytic Leukemia: Prognostic Factors, Supportive Care Issues and Therapeutic Advances 2017 Master Class Course John C. Byrd, MD D Warren Brown Chair of Leukemia Research Distinguished University
More informationMolecular Pathology Evaluation Panel and Molecular Pathology Consortium Advice Note
Molecular Pathology Evaluation Panel and Molecular Pathology Consortium Advice Note MPEP/MPC Advice Note 2016-02 June 2016 Test evaluated: Tumour Protein p53 (TP53) Molecular Pathology Evaluation Panel
More informationTP53 ABERRATIONS Methodical considerations
TP53 ABERRATIONS Methodical considerations Sarka Pavlova University Hospital and Masaryk University, Brno, Czech republic Belgrade March 16-17, 2018 TP53 gene in CLL: modes of inactivation mutation(s)
More informationMRD Negativity as an Outcome in CLL: Ongoing Challenges with Del 17p Patients
MRD Negativity as an Outcome in CLL: Ongoing Challenges with Del 17p Patients Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute Associate Professor Harvard Medical School November
More informationThe Past, Present, and Future of Acute Myeloid Leukemia
The Past, Present, and Future of Acute Myeloid Leukemia Carter T. Davis, MD Hematology-Oncology Fellow Duke University Health System September 10, 2016 Overview Overview of Acute Myeloid Leukemia Review
More informationRaising the Bar in CLL Michael E. Williams, MD, ScM Byrd S. Leavell Professor of Medicine Chief, Hematology/Oncology Division
Raising the Bar in CLL Michael E. Williams, MD, ScM Byrd S. Leavell Professor of Medicine Chief, Hematology/Oncology Division University of Virginia Cancer Center The Clinical Continuum of CLL Early asymptomatic
More informationHow I treat high risck CML
Torino, September 14, 2018 How I treat high risck CML Patrizia Pregno Hematology Dept. Citta della Salute e della Scienza Torino Disclosures Advisory Board: Novartis, Pfizer, Incyte Speaker Honoraria:
More informationQuando e se è possibile e u/le o0enere una remissione completa
Quando e se è possibile e u/le o0enere una remissione completa 1) Clinical heterogeneity Disease characteris:cs Pa:ent characteris:cs 2) Modern chemoimmunotherpy approaches 3) New mechanism- based treatment
More informationPrognostic Scoring Systems for Therapeutic Decision Making in MDS. Peter Greenberg, MD Stanford University Cancer Center Stanford, CA
Prognostic Scoring Systems for Therapeutic Decision Making in MDS Peter Greenberg, MD Stanford University Cancer Center Stanford, CA DISCLOSURE I have no relevant financial relationships to disclose. MDSs:
More informationCLL treatment algorithm and state of the art
CLL treatment algorithm and state of the art Davide Rossi, M.D., Ph.D. Hematology IOSI - Oncology Institute of Southern Switzerland IOR - Institute of Oncology Research Bellinzona - Switzerland CLL subgroups
More informationDFCR. Dept. of Medical Oncology, Dana-Farber Cancer Institute 2. Dept. of Medical Oncology, Beth Israel Deaconess Medical Center Boston, USA
A Phase IB/II Study of Duvelisib in Combination with FCR (DFCR) For Frontline Therapy for Younger CLL Patients DFCR Matthew S. Davids, MD, MMSc 1, David C. Fisher, MD 1, Svitlana Tyekucheva, PhD 1, Haesook
More informationCLL & SLL: Current Management & Treatment. Dr. Isabelle Bence-Bruckler
CLL & SLL: Current Management & Treatment Dr. Isabelle Bence-Bruckler Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of white blood cell B lymphocyte Lymphocytic Cancer
More informationPublished Ahead of Print on March 15, 2018, as doi: /haematol Copyright 2018 Ferrata Storti Foundation.
Published Ahead of Print on March 15, 2018, as doi:10.3324/haematol.2017.183350. Copyright 2018 Ferrata Storti Foundation. Long-term follow-up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide
More informationOutcomes of patients with CLL after discontinuing idelalisib
Outcomes of patients with CLL after discontinuing idelalisib Jacqueline C. Barrientos, Manmeen Kaur, Alexis Mark, Jaewon Chung, Nancy Driscoll, Alison Bender, Kanti R. Rai ASH Annual Meeting Abstracts
More informationThe mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment
INDIVIDUALIZING THERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment Gianluca Gaidano 1 and Davide Rossi 2,3 1 Division
More informationREAL LIFE AMBULATORIALE E STUDI CLINICI RANDOMIZZATI NELLA PROGRAMMAZIONE TERAPEUTICA DELLA LEUCEMIA LINFATICA CRONICA.
REAL LIFE AMBULATORIALE E STUDI CLINICI RANDOMIZZATI NELLA PROGRAMMAZIONE TERAPEUTICA DELLA LEUCEMIA LINFATICA CRONICA Roberta Murru Struttura Complessa Ematologia e Centro Trapianti Presidio Ospedaliero
More informationCLL: MRD as a Surrogate Endpoint for Clinical Trials White Oak February 27, Chronic Lymphocytic Leukemia. Paolo Ghia
CLL: MRD as a Surrogate Endpoint for Clinical Trials White Oak February 27, 2013 Chronic Lymphocytic Leukemia Paolo Ghia CLL: MRD as a Surrogate Endpoint for Clinical Trials White Oak February 27, 2013
More informationUpdate: Chronic Lymphocytic Leukemia
ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8
More informationAktuelle Therapiestandards und neue Entwicklungen bei der CLL Primärtherapie und Risikostratifikation
Aktuelle Therapiestandards und neue Entwicklungen bei der CLL Primärtherapie und Risikostratifikation Dr. med. Petra Langerbeins Universitätsklinik Köln Deutsche CLL Studiengruppe (DCLLSG) OFFENLEGUNG
More informationImproving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy
New Evidence reports on presentations given at ASH 2009 Improving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy From ASH 2009: Chronic Lymphocytic Leukemia
More informationAddition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial
Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Hallek M et al. Lancet 2010;376:1164-74. Introduction > In patients with CLL, the
More informationPathology of the indolent B-cell lymphomas Elias Campo
Pathology of the indolent B-cell lymphomas Elias Campo Hospital Clinic, University of Barcelona Small B-cell lymphomas Antigen selection NAIVE -B LYMPHOCYTE MEMORY B-CELL MCL FL LPL MZL CLL Small cell
More informationChronic lymphocytic leukemia
Chronic lymphocytic leukemia Heterogeneous course Heterogeneouse response to therapy What is the biological basis for this variability? Prognostic markers Choice of therapy Development of new treatment
More informationCLL: disease specific biology and current treatment. Dr. Nathalie Johnson
CLL: disease specific biology and current treatment Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck
More informationIPSS Modified 7/27/2011. WHO-Based Prognostic Scoring System (WPSS)
Advances in MDS Treatment: What s on the Horizon? New Prognostic Models and Therapies Jason Gotlib, MD, MS Assistant Professor of Medicine (Hematology) Stanford Cancer Center AA&MDSIF July 3, 011 WHO-Based
More informationOutcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion
ARTICLES Chronic Lymphocytic Leukemia Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion Paolo Strati, Michael J. Keating, Susan M. O Brien, Alessandra Ferrajoli, Jan Burger,
More informationState of the Art Treatment for Relapsed Mantle Cell Lymphoma
Winship Cancer Institute of Emory University State of the Art Treatment for Relapsed Mantle Cell Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor, BMT Program Emory University- Winship Cancer Institute
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationMED B Form CLL. Johannes Schetelig. London 09/April/
www.ebmt.org MED B Form CLL Johannes Schetelig London 09/April/2013 Content Update on CLL (15 ) Experiment with mini MED B CLL Assessment of pre-treatment in CLL Cytogenetics in CLL What is the IGVH-Gene
More informationRecurrent gene mutations in chronic lymphocytic leukemia: An ERIC project within HARMONY
Bench to Bedside Project Recurrent gene mutations in chronic lymphocytic leukemia: An ERIC project within HARMONY Lesley Ann Sutton Uppsala Universitet Sweden 43 rd ERIC GENERAL ASSEMBLY HARMONY: A European
More informationReporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota
Reporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota Reporting cytogenetics What is it? Terminology Clinical value What details are important Diagnostic Tools for Leukemia
More informationMonosomal Karyotype Provides Better Prognostic Prediction after Allogeneic Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia
Monosomal Karyotype Provides Better Prognostic Prediction after Allogeneic Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia Betul Oran, 1 Michelle Dolan, 2 Qing Cao, 1 Claudio Brunstein,
More informationBIOGRAPHICAL SKETCH NAME: ANASTASIA CHATZIDIMITRIOU POSITION TITLE: SENIOR RESEARCHER
BIOGRAPHICAL SKETCH NAME: ANASTASIA CHATZIDIMITRIOU POSITION TITLE: SENIOR RESEARCHER EDUCATION/TRAINING: BIOLOGY INSTITUTION AND LOCATION Completion Date FIELD OF STUDY ARISTOTLE UNIVERSITY OF THESSALONIKI
More information15 th Annual Miami Cancer Meeting
15 th Annual Miami Cancer Meeting CLL and CML Mohamed A. Kharfan-Dabaja, MD, MBA, FACP Director, Blood and Marrow Transplantation and Cellular Therapies Mayo Clinic Jacksonville, FL 15 th Annual Miami
More informationSplenic marginal zone NHL: Update on biology and therapy. Jonathan W. Friedberg M.D., M.M.Sc.
Splenic marginal zone NHL: Update on biology and therapy Jonathan W. Friedberg M.D., M.M.Sc. Marginal zone NHL: A Neglected Lymphoma? Marginal zone NHL/MALT; 3 rd most common B-cell NHL Al-Hamadani et
More informationManagement of Chronic Lymphatic Leukemia Beyond conventional therapy
3 rd Young Hematologists Orientation Program SGPGI Lucknow August 18 th -19 th 218 Management of Chronic Lymphatic Leukemia Beyond conventional therapy Prof. Hari Menon. MD DM Department of Hemato-Oncology
More informationRisikoprofil-gesteuerte, individualisierte Therapiestrategien bei der CLL. Michael Hallek University of Cologne
Risikoprofil-gesteuerte, individualisierte Therapiestrategien bei der CLL Michael Hallek University of Cologne 100 90 80 70 60 Substantial progress in CLL therapy in one decade 50 40 complete remissions
More informationCLL Complete SM Report
Reported: 02/01/2012 Σ CGI ID No:5 Client:r Client Address: CLINICAL DATA: Lymphoma No CBC results provided. CLL Complete SM Report FINAL DIAGNOSIS: CD19+ B cell lymphoma, ZAP-70 + (44%), with borderline
More informationASH up-date: Changing the Standard of Care for Patients with. (or: Who to treat with What When?)
ASH up-date: Changing the Standard of Care for Patients with B-cell Chronic Lymphocytic Leukaemia (or: Who to treat with What When?) Dr Anna Schuh, MD, PhD, MRCP, FRCPath Consultant and Senior Lecturer
More informationRESEARCH ARTICLE. Introduction. Methods Wiley Periodicals, Inc.
BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase AJH Dennis (Dong Hwan) Kim, 1 * Nada Hamad,
More informationMantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients
Mantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients Olivier Hermine MD, PhD Department of Hematology INSERM and CNRS, Imagine Institute Necker Hospital Paris, France
More informationBR is an established treatment regimen for CLL in the front-line and R/R settings
Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory CLL: Results of a phase III randomized double-blind placebo-controlled study Andrew D. Zelenetz,
More informationThe genetic landscape of high-risk CLL
The genetic landscape of high-risk CLL Jonathan Strefford PhD Reader in Molecular Haematology Cancer Genomics Treatment development 2010 Further development of Small molecules for Stratified CLL treatment
More informationManagement of Multiple Myeloma
Management of Multiple Myeloma Damian J. Green, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance New Treatment Options Have Improved OS in MM Kumar SK, et al. Blood. 2008;111:2516-2520.
More informationHighlights in chronic lymphocytic leukemia
Congress Highlights CLL Highlights in chronic lymphocytic leukemia A. Janssens, MD, PhD 1 As new data on indolent non-hodgkin lymphoma (inhl) were not that compelling, only highlights on chronic lymphocytic
More informationHeng Li, Wenjie Xiong, Huimin Liu, Shuhua Yi, Zhen Yu, Wei Liu, Rui Lyu, Tingyu Wang, Dehui Zou, Zengjun Li, Lugui Qiu
Original Article Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China Heng Li, Wenjie Xiong, Huimin
More informationTemplate for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version: CLLBiomarkers 1.0.0.2 Protocol Posting Date: June 2017
More informationCOMy Congress A New Era of Advances in Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
A New Era of Advances in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive
More informationBENDAMUSTINE + RITUXIMAB IN CLL
BENDAMUSTINE + RITUXIMAB IN CLL Barbara Eichhorst Bologna 13. November 2017 CONFLICT OF INTERESTS 1. Advisory Boards Janssen, Gilead, Roche, Abbvie, GSK 2. Honoraria Roche, GSK, Gilead, Janssen, Abbvie,
More informationIdelalisib given front-line for the treatment of CLL results in frequent and severe immune-mediated toxicities
Idelalisib given front-line for the treatment of CLL results in frequent and severe immune-mediated toxicities Benjamin L. Lampson, Tiago R. Matos, Siddha N. Kasar, Haesook Kim, Elizabeth A. Morgan, Laura
More information